Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors
Phase 1
9 Years
N/A
9 Years
N/A
Not Enrolling
Both
Sarcoma, Ewing's
Both
Sarcoma, Ewing's
Trial Information
Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors
Inclusion Criteria:
- Diagnosis of Ewing's sarcoma family tumors
Exclusion Criteria:
- Concurrent treatment with any other anti tumor agents
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety and tolerability of CP-751,871
Outcome Time Frame:
approximately 76 months
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A4021010
NCT ID:
NCT00474760
Start Date:
August 2005
Completion Date:
October 2012
Related Keywords:
- Sarcoma, Ewing's
- Sarcoma, Ewing's
- Sarcoma
Name | Location |
|---|---|
| Pfizer Investigational Site | Detroit, Michigan 48201 |
| Pfizer Investigational Site | Rochester, Minnesota 55905 |
